Article Text
PDFEditorial commentary
Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis
Statistics from Altmetric.com
Footnotes
Contributors HM drafted the text, and MM and SK supervised and made revisions.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.